Literature DB >> 18616531

MLPA and cDNA analysis improves COL4A5 mutation detection in X-linked Alport syndrome.

J M Hertz1, I Juncker, N Marcussen.   

Abstract

The X-linked form of Alport syndrome (AS) is caused by mutations in the COL4A5 gene encoding the alpha5 chain of type IV collagen. Most COL4A5 mutations are individual, and mutation analysis is complicated by the size of the gene and the number of exons. Larger structural rearrangements account for 10-15% of mutations. We have established a method for mutation analysis of COL4A5 based on reverse transcriptase-polymerase chain reaction analysis of mRNA from cultured skin fibroblasts and multiplex ligation-dependent probe amplification (MLPA) on genomic DNA. One advantage of using skin biopsies for the mRNA analysis is the possibility of immunohistochemical staining for the alpha5(IV) chain on skin sections to support a diagnosis of X-linked AS. A mutation was detected in all five cases included. One patient presenting with AS and diffuse leiomyomatosis was found to have a COL4A5 deletion extending into and comprising COL4A6 exons 1, 1', and 2. We have evaluated the MLPA assay on samples from 67 previously tested AS patients (45 males and 22 females) and 20 controls. We found that the combination of cDNA and MLPA analysis improves the mutation detection rate in COL4A5 and that MLPA should be the first step in genetic testing for X-linked AS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18616531     DOI: 10.1111/j.1399-0004.2008.01051.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  6 in total

1.  Clinical utility gene card for: Alport syndrome.

Authors:  Jens Michael Hertz; Mads Thomassen; Helen Storey; Frances Flinter
Journal:  Eur J Hum Genet       Date:  2011-12-14       Impact factor: 4.246

2.  Detection by multiplex ligation-dependent probe amplification of large deletion mutations in the COL4A5 gene in female patients with Alport syndrome.

Authors:  Kandai Nozu; Rafal Przybyslaw Krol; Koichi Nakanishi; Norishige Yoshikawa; Yoshimi Nozu; Yasufumi Ohtsuka; Kazumoto Iijima; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2009-01-24       Impact factor: 3.714

3.  Characterization of contiguous gene deletions in COL4A6 and COL4A5 in Alport syndrome-diffuse leiomyomatosis.

Authors:  Kandai Nozu; Shogo Minamikawa; Shiro Yamada; Masafumi Oka; Motoko Yanagita; Naoya Morisada; Shuichiro Fujinaga; China Nagano; Yoshimitsu Gotoh; Eihiko Takahashi; Takahiro Morishita; Tomohiko Yamamura; Takeshi Ninchoji; Hiroshi Kaito; Ichiro Morioka; Koichi Nakanishi; Igor Vorechovsky; Kazumoto Iijima
Journal:  J Hum Genet       Date:  2017-03-09       Impact factor: 3.172

4.  Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2.

Authors:  Vera Uliana; Elena Marcocci; Mafalda Mucciolo; Ilaria Meloni; Claudia Izzi; Carlo Manno; Mirella Bruttini; Francesca Mari; Francesco Scolari; Alessandra Renieri; Leonardo Salviati
Journal:  Pediatr Nephrol       Date:  2010-12-14       Impact factor: 3.714

5.  Identification of 47 novel mutations in patients with Alport syndrome and thin basement membrane nephropathy.

Authors:  Stefanie Weber; Katja Strasser; Sabine Rath; Achim Kittke; Sonja Beicht; Martin Alberer; Bärbel Lange-Sperandio; Peter F Hoyer; Marcus R Benz; Sabine Ponsel; Lutz T Weber; Hanns-Georg Klein; Julia Hoefele
Journal:  Pediatr Nephrol       Date:  2016-01-25       Impact factor: 3.714

6.  Clinical utility gene card for: Alport syndrome - update 2014.

Authors:  Jens Michael Hertz; Mads Thomassen; Helen Storey; Frances Flinter
Journal:  Eur J Hum Genet       Date:  2014-11-12       Impact factor: 4.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.